Speciality Medicines to Raise ₹29 Crore via IPO on BSE SME

Why It Matters

The capital raise will enable Speciality Medicines to accelerate R&D and global market entry, strengthening its position in fast‑growing high‑margin therapeutic segments. This IPO also signals rising investor appetite for Indian specialty pharma firms.

Key Takeaways

• IPO aims to raise ₹29 crore
• 23.5 lakh shares priced ₹117‑₹124
• Funds target R&D centre and global expansion
• Focus on oncology, immunology, neurology markets
• Unistone Capital leads book‑running; Skyline registers issue

Pulse Analysis

India’s specialty pharmaceutical segment is witnessing double‑digit growth, driven by rising demand for high‑value therapies in oncology, immunology and neurology. Smaller, agile firms are increasingly turning to capital markets to fund scale‑up initiatives, and the BSE SME platform has become a favored conduit for such fundraising. By tapping public capital, companies can bridge the gap between domestic distribution strength and the costly R&D pipelines required for next‑generation drugs, positioning themselves for both domestic dominance and export opportunities.

Speciality Medicines leverages a robust distribution network that spans over 20 states and multiple international markets, giving it a competitive edge in delivering niche therapies to hospitals and specialty clinics. The IPO proceeds earmarked for a dedicated R&D centre signal a strategic shift from pure distribution to end‑to‑end product development, allowing the firm to co‑create or acquire novel compounds tailored to its high‑margin therapeutic focus. Coupled with plans for international product registration, the company aims to diversify revenue streams and reduce reliance on the price‑sensitive Indian market.

For investors, the offering presents exposure to a sector poised for sustained expansion, underpinned by demographic trends and increasing healthcare spending. The involvement of Unistone Capital as book‑running lead manager adds credibility, while the modest price band offers an attractive entry point relative to peers. As specialty pharma continues to attract venture and public capital, firms that combine strong distribution with in‑house innovation, like Speciality Medicines, are likely to outperform and drive broader market consolidation.

Deal Summary

Speciality Medicines, a distributor of specialty pharmaceutical products, announced an IPO on the BSE SME platform to raise ₹29 crore by issuing 23.5 lakh equity shares at a price band of ₹117‑₹124 per share, opening on March 20. Unistone Capital will act as the book‑running lead manager and Skyline Financial Services as registrar. Proceeds will fund R&D, product registration, marketing, working‑capital and other corporate purposes.